Retracing the Lineage of Cancer Cells – Technology Networks
By daniellenierenberg
There is no stronger risk factor for cancer than age. At the time of diagnosis, the median age of patients across all cancers is 66. That moment, however, is the culmination of years of clandestine tumor growth, and the answer to an important question has thus far remained elusive: When does a cancer first arise?
At least in some cases, the original cancer-causing mutation could have appeared as long as 40 years ago, according to a new study by researchers at Harvard Medical School and the Dana-Farber Cancer Institute.
Reconstructing the lineage history of cancer cells in two individuals with a rare blood cancer, the team calculated when the genetic mutation that gave rise to the disease first appeared. In a 63-year-old patient, it occurred at around age 19; in a 34-year-old patient, at around age 9.
The findings, published in the March 4 issue ofCell Stem Cell, add to a growing body of evidence that cancers slowly develop over long periods of time before manifesting as a distinct disease. The results also present insights that could inform new approaches for early detection, prevention, or intervention.
"For both of these patients, it was almost like they had a childhood disease that just took decades and decades to manifest, which was extremely surprising," said co-corresponding study author Sahand Hormoz, HMS assistant professor of systems biology at Dana-Farber.
"I think our study compels us to ask, when does cancer begin, and when does being healthy stop?" Hormoz said. "It increasingly appears that it's a continuum with no clear boundary, which then raises another question: When should we be looking for cancer?"
In their study, Hormoz and colleagues focused on myeloproliferative neoplasms (MPNs), a rare type of blood cancer involving the aberrant overproduction of blood cells. The majority of MPNs are linked to a specific mutation in the gene JAK2. When the mutation occurs in bone marrow stem cells, the body's blood cell production factories, it can erroneously activate JAK2 and trigger overproduction.
To pinpoint the origins of an individual's cancer, the team collected bone marrow stem cells from two patients with MPN driven by the JAK2 mutation. The researchers isolated a number of stem cells that contained the mutation, as well normal stem cells, from each patient, and then sequenced the entire genome of each individual cell.
Over time and by chance, the genomes of cells randomly acquire so-called somatic mutations--nonheritable, spontaneous changes that are largely harmless. Two cells that recently divided from the same mother cell will have very similar somatic mutation fingerprints. But two distantly related cells that shared a common ancestor many generations ago will have fewer mutations in common because they had the time to accumulate mutations separately.Cell of origin
Analyzing these fingerprints, Hormoz and colleagues created a phylogenetic tree, which maps the relationships and common ancestors between cells, for the patients' stem cells--a process similar to studies of the relationships between chimpanzees and humans, for example.
"We can reconstruct the evolutionary history of these cancer cells, going back to that cell of origin, the common ancestor in which the first mutation occurred," Hormoz said.
Combined with calculations of the rate at which mutations accumulate, the team could estimate when the JAK2 mutation first occurred. In the patient who was first diagnosed with MPN at age 63, the team found that the mutation arose around 44 years prior, at the age of 19. In the patient diagnosed at age 34, it arose at age 9.
By looking at the relationships between cells, the researchers could also estimate the number of cells that carried the mutation over time, allowing them to reconstruct the history of disease progression.
"Initially, there's one cell that has the mutation. And for the next 10 years there's only something like 100 cancer cells," Hormoz said. "But over time, the number grows exponentially and becomes thousands and thousands. We've had the notion that cancer takes a very long time to become an overt disease, but no one has shown this so explicitly until now."
The team found that the JAK2 mutation conferred a certain fitness advantage that helped cancerous cells outcompete normal bone marrow stem cells over long periods of time. The magnitude of this selective advantage is one possible explanation for some individuals' faster disease progression, such as the patient who was diagnosed with MPN at age 34.
In additional experiments, the team carried out single-cell gene expression analyses in thousands of bone marrow stem cells from seven different MPN patients. These analyses revealed that the JAK2 mutation can push stem cells to preferentially produce certain blood cell types, insights that may help scientists better understand the differences between various MPN types.
Together, the results of the study offer insights that could motivate new diagnostics, such as technologies to identify the presence of rare cancer-causing mutations currently difficult to detect, according to the authors.
"To me, the most exciting thing is thinking about at what point can we detect these cancers," Hormoz said. "If patients are walking into the clinic 40 years after their mutation first developed, could we have caught it earlier? And could we prevent the development of cancer before a patient ever knows they have it, which would be the ultimate dream?"
The researchers are now further refining their approach to studying the history of cancers, with the aim of helping clinical decision-making in the future.
While their approach is generalizable to other types of cancer, Hormoz notes that MPN is driven by a single mutation in a very slow growing type of stem cell. Other cancers may be driven by multiple mutations, or in faster-growing cell types, and further studies are needed to better understand the differences in evolutionary history between cancers.
The team's current efforts include developing early detection technologies, reconstructing the histories of greater numbers of cancer cells, and investigating why some patients' mutations never progress into full-blown cancer, but others do.
"Even if we can detect cancer-causing mutations early, the challenge is to predict which patients are at risk of developing the disease, and which are not," Hormoz said. "Looking into the past can tell us something about the future, and I think historical analyses such as the ones we conducted can give us new insights into how we could be diagnosing and intervening."
Reference:Egeren DV, Escabi J, Nguyen M, et al. Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms. Cell Stem Cell. 2021;28(3):514-523.e9. doi:10.1016/j.stem.2021.02.001
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.
Read the original post:
Retracing the Lineage of Cancer Cells - Technology Networks
- Timely Bone Marrow Transplant by Fortis gives new lease of life to a patient with Multiple Myeloma - APN News - April 4th, 2021
- Orca-T Offers an Alternative to HSCT With Improved Patient Experience - OncLive - April 4th, 2021
- Do Therapies for Alzheimer's & Parkinson's that Clear Abnormal Brain Proteins Make the Diseases Worse? - BioSpace - April 4th, 2021
- LGL Leukemia: Overview, Symptoms, and Treatment - Healthline - April 4th, 2021
- BioRestorative Therapies Announces Notice of Allowance for a New Patent Application Related to its Off-the-Shelf ThermoStem Program - GlobeNewswire - April 4th, 2021
- All About Multiple Myeloma, Type of Blood Cancer Kirron Kher is Suffering From - India.com - April 4th, 2021
- Heres what happens when a beam of subatomic particles hits you in the face - The Next Web - April 4th, 2021
- Black people are three times less likely to find a bone marrow donor than white people - WLNS - March 8th, 2021
- Bone Marrow-Derived Stem Cells (BMSCS) Market To Witness Relatively Significant Growth During Forecast to 2027 The Courier - The Courier - March 8th, 2021
- Stem Cell Therapy Market expected to reach USD 16.51 Billion by 2025 KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper - March 8th, 2021
- An 8-year-olds search for bone marrow match in battle with leukemia comes to North Texas - The Dallas Morning News - March 8th, 2021
- Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using StemSpine... - March 8th, 2021
- Magenta Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Program Highlights - Tullahoma News and Guardian - March 8th, 2021
- COSELA (trilaciclib) for the Treatment of Chemotherapy-Induced Myelosuppression - Clinical Trials Arena - March 8th, 2021
- U. Cancer Center pilot projects: investigating cancer connections - The Brown Daily Herald - March 8th, 2021
- 'Like finding a needle on the bottom of the ocean': Local teen finds perfect bone marrow match - CTV News Edmonton - March 8th, 2021
- Meet the women hoping to recruit more stem cells donors from Black communities - CTV News - February 19th, 2021
- N.J. mom of 4 has leukemia. A bone marrow registry is being held Saturday. - nj.com - February 19th, 2021
- Polycythemia vera life expectancy: With treatment and more - Medical News Today - February 19th, 2021
- Novartis and Gates Foundation Team Up To Deliver Affordable Sickle Cell Gene Therapy - BioSpace - February 19th, 2021
- Heartbreak for family of cancer-stricken four-year-old as stem cell donor falls ill at last minute - Press and Journal - February 19th, 2021
- Initiation of Post-Primary Tuberculosis of the Lungs: Exploring the Secret Role of Bone Marrow Derived Stem Cells - DocWire News - February 17th, 2021
- Jasper Therapeutics Announces Launch of New Clinical Trial with National Heart, Lung, and Blood Institute to Evaluate JSP191 in Sickle Cell Disease -... - February 17th, 2021
- Cord Blood Banking Services Market projected to expand at a CAGR of 10.9% from 2019 to 2027 KSU | The Sentinel Newspaper - KSU | The Sentinel... - February 17th, 2021
- After 13 years of trials and tribulations RTP firm G1 wins first FDA approval for cancer drug - WRAL Tech Wire - February 17th, 2021
- Novartis, Gates Foundation pursue a simpler gene therapy for sickle cell - STAT - February 17th, 2021
- Be The Match encourages people of color to join bone marrow registry - KING5.com - February 14th, 2021
- Types of leukemia: Prevalence, treatment options, and prognosis - Medical News Today - February 14th, 2021
- Global Stem Cell Therapy Market Set to Reach USD 214.5 Million by 2024 - The Courier - February 14th, 2021
- Bone marrow transplant shows signs of curing brave little boy with one in a million condition - Shields Gazette - February 14th, 2021
- Arlo's Army needs stem cell donor as mum begs for help to save three-year-old's life - Glasgow Live - February 14th, 2021
- Ensuring gut integrity may improve results in blood cancer: Study - Hindustan Times - February 14th, 2021
- Keep it Flowing: Combating COVID-19 Blood Shortages in Cancer Treatment - Curetoday.com - February 14th, 2021
- Family's resilience heartwarming - The Friday Flyer - February 14th, 2021
- Apamistamab Conditioning Treatment Induces High Rates of HCT Success in AML - OncLive - February 11th, 2021
- Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Patients with... - February 11th, 2021
- Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 2021 TCT Meetings of... - February 11th, 2021
- World Symposium Orchard leads the crop of Hurler syndrome hopefuls - Vantage - February 11th, 2021
- Growth Factors of Hematopoietic Stem Cell Transplantation (HSCT) Market with Emerging Trends and Revenue Estimation By 2026 - AlgosOnline - February 11th, 2021
- I Survived Cancer, and Then I Needed to Remember How to Live - The Atlantic - February 10th, 2021
- Researchers curb local immune response in horses receiving stem cell injury therapy - Horsetalk - February 7th, 2021
- Cord Blood Banking: Myths And Facts You Should Be Aware Of, As Per Expert - NDTV Doctor - February 7th, 2021
- After Bone Marrow Donation Saves 9-Year-Old Boy With Cancer, Boston Mom Fights To Raise Awareness - Here And Now - February 6th, 2021
- Leukemia in children: Symptoms, causes, treatment, outlook, and more - Medical News Today - February 6th, 2021
- Perales Examines the Impact of COVID-19 on Recipients of Cellular Therapies for Cancer - OncLive - February 6th, 2021
- US Man Who Wants to Live for 180 Years Re-injects His Own Stem Cells, Spends Rs 87 Lakh - News18 - February 6th, 2021
- Hypermethylation-mediated downregulation of long non-coding RNA MEG3 inhibits osteogenic differentiation of bone marrow mesenchymal stem cells and... - February 6th, 2021
- Family 'living worst nightmare' as they desperately seek donor for tot with rare blood cancer - Teesside Live - February 6th, 2021
- Stem cells efficacy confirmed in treating ototoxic hearing loss - Korea Biomedical Review - February 4th, 2021
- Understanding bone marrow transplant: The guidelines and the protocols - The New Indian Express - February 4th, 2021
- Man who wants to live for 180 years spends Rs 18 lakh to re-inject his own stem cells - Times Now - February 4th, 2021
- World Cancer Day 2021: DKMS Announces The Milestone Of Giving 90,000 Blood Cancer Patients Worldwide A Second Chance At Life - PR Newswire India - February 4th, 2021
- Hematopoietic Stem Cell Transplantation (HSCT) Market Incredible Possibilities, Growth With Industry Study, Detailed Analysis And Forecast To 2027 ... - February 4th, 2021
- Novel Bone Marrow 'Ingredient' To Help Arthritic Horses The Horse - TheHorse.com - February 3rd, 2021
- 'Whatever it takes': Stem cell drive underway to find bone marrow match for girl on Alta. First Nation - CTV Edmonton - February 3rd, 2021
- Why Cynata is hopeful its COVID treatment trial will succeed where others have failed - Business News Australia - February 3rd, 2021
- Helping others helps Havard through sickness | Community | hannapub.com - The Franklin Sun - February 3rd, 2021
- Anti-Emetic Drug Effectively Blocks CD93 Signaling in Preclinical Evaluations, Suggesting Suitability in CML - Cancer Therapy Advisor - February 3rd, 2021
- [Full text] Retrospective Study on Implantation of Autologous-Cultured Osteoblasts | ORR - Dove Medical Press - February 3rd, 2021
- India Stem Cell Market speedy growth at US$ 1.27 Bn by 2028 with Thermofisher Scientific India, Pluristem Technologies, Becton Dickinson Private... - February 3rd, 2021
- World Cancer Day 2021: Know All About The Different Types Of Blood Cancer From Expert - NDTV Doctor - February 3rd, 2021
- MPN Efforts Set Sights on Improved Survival and Symptom Burden - OncLive - February 3rd, 2021
- World Cancer Day 2021: Know The Symptoms And Risk Factors Of Leukemia - NDTV Doctor - February 3rd, 2021
- GEMoaB Announces UniCAR-T-CD123 Data from its Ongoing Phase I Study in Patients with Relapsed/Refractory AML (rrAML) to be Presented at Virtual 3rd... - February 3rd, 2021
- Covid-19 leads to shortage of bone marrow donors - GO! and Express - January 31st, 2021
- What Is Leukemia: And How To Prevent It? - Technology Times Pakistan - January 31st, 2021
- Stem Cell Therapy Market 2021: Global Key Players, Trends, Share, Industry Size, Segmentation, Forecast To 2027 KSU | The Sentinel Newspaper - KSU |... - January 29th, 2021
- UTV documentary tells of young Belfast woman's lasting legacy to promote stem cell donation - The Irish News - January 29th, 2021
- National Institute for Health and Care Excellence (NICE) recommends lenalidomide as a maintenance therapy for people with newly diagnosed multiple mye... - January 29th, 2021
- BrainStorm-Cell Therapeutics to Announce Fourth Quarter and Fiscal Year 2020 Financial Results and Provide a Corporate Update - Yahoo Finance - January 29th, 2021
- Every day is a success for little boy with leukaemia after life-saving transplant - Grimsby Live - January 27th, 2021
- If I Have Cancer, Dementia or MS, Should I Get the Covid Vaccine? - Kaiser Health News - January 27th, 2021
- [Full text] Post-Transplant Maintenance Therapy for Patients with Acute Myeloid Le | JBM - Dove Medical Press - January 27th, 2021
- Onward and Upward for Single-Use Systems in Bioprocessing - Medical Device and Diagnostics Industry - January 27th, 2021
- From Kochi, with love - Stem cell donor meets infant survivor after two years - The New Indian Express - January 25th, 2021
- Stem Cell Therapy Market Size, Growth Opportunities, Trends, Key Players and Forecast to 2027 - The Courier - January 23rd, 2021
- Global Cell Isolation Market SWOT Analysis, Key Indicators, Forecast 2027 : Becton, Dickinson, and Company, Thermo Fisher Scientific KSU | The... - January 23rd, 2021
- Adipose Derived Stem Cell Therapy Market 2018: Production, Sales, Supply, Demand, Analysis and Forecast To 2026 | BioRestorative Therapies, Inc.,... - January 23rd, 2021
- 'I was excited to help somebody': Montana Western's Dylan Pope reflects on donating bone marrow - MontanaSports - January 22nd, 2021
- Global Bone Marrow-Derived Stem Cells (BMSCS) Market 2021 Overview, Trends, Growth Factors and Leading Players With Detailed Analysis of Industry... - January 22nd, 2021
